A BeiGene cancer immunotherapy has received a long anticipated approval, but the regulatory win comes as the company loses its partnership on the drug with Novartis, which had inked the global ...

BeOne’s subsidiary Guangzhou BeOne Medicines Biopharmaceutical signed a licensing agreement with Huahui Health to obtain the ...

BeiGene ONC is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating that BeiGene ...

Eleven months after breaking ground, biopharmaceutical company BeiGene celebrated a milestone for its $700 million manufacturing and R&D facility in Hopewell. On March 21, the last piece of structural ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today reinforced ...

“This site is going to help us develop and bring medicines to millions and millions more patients,” BeiGene co-founder, Chairman and CEO John Oyler enthused during the global oncology company’s recent ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal ...

BeiGene's innovative and diverse product pipeline, including Brukinsa and Tislelizumab, positions the company at the forefront of the oncology space. BeiGene's sound financial health, demonstrated by ...

Three years with a front-row seat for the development of DKN-01 have failed to persuade BeiGene to pull the trigger on a deal for the oncology drug candidate, leaving Leap Therapeutics looking for a ...

BeiGene Ltd (NASDAQ:BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks. AbbVie’s (NYSE:ABBV) patent case, which claims ...

Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday. The stock opened at $179.86, then climbed to a daily high of $202.90 in the first hour of ...

AbbVie has filed a lawsuit against BeiGene, alleging the biotechnology company of stealing trade secrets to develop a competing cancer therapy. The lawsuit, filed Sept. 6, alleges that former AbbVie ...